Abstract | INTRODUCTION: AREAS COVERED: The data are obtained by searching in the PubMed database. The search terms used included antiangiogenic therapy, TB-403 ( RO5323441), placenta growth factor (PlGF) and VEGFR-1 (Flt-1). We review preclinical data concerning the function and inhibition of PlGF and summarize data on expression of PlGF in cancer patients. Data from early-phase clinical trials of TB-403 ( RO5323441), a monoclonal antibody inhibiting PlGF, are discussed. Future development strategies, therapeutic potentials and limitations of TB-403 are further evaluated. EXPERT OPINION: There are some conflicting data on the function of PlGF and the importance of its role in primary tumor growth. Data from some preclinical models of PlGF inhibition and early-phase clinical trials with TB-403 are, however, promising, although the true potential of the drug is yet to be determined. Further clinical development should be preceded by molecular studies in the context of well-designed preclinical models and/or small translational studies. Future challenges involve identifying predictive biomarkers.
|
Authors | Dorte Lisbet Nielsen, Lisa Sengeløv |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 12
Issue 6
Pg. 795-804
(Jun 2012)
ISSN: 1744-7682 [Electronic] England |
PMID | 22506966
(Publication Type: Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- PGF protein, human
- Pregnancy Proteins
- Placenta Growth Factor
- TB-403
|
Topics |
- Angiogenesis Inhibitors
(adverse effects, therapeutic use)
- Animals
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Humans
- Neoplasms
(blood supply, drug therapy, metabolism, pathology)
- Neovascularization, Pathologic
(metabolism, prevention & control)
- Placenta Growth Factor
- Pregnancy Proteins
(antagonists & inhibitors, metabolism)
- Signal Transduction
(drug effects)
- Treatment Outcome
|